Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective

Blood Pressure

Volumn 17, Issue 5-6, 2008, Pages 260-269

  Kjeldsen, Sverre E ^a,d   Weber, Michael ^b   Oparil, Suzanne ^c   Jamerson, Kenneth A ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b SUNY Downstate Medical Center   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiotensin II type 1 receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive agents; Calcium channel blockers; Hypertension; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LOOP DIURETIC AGENT; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MEDICAL RESEARCH; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; SYNCOPE; SYSTOLIC HYPERTENSION; TASTE DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 58049112068     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050802565171     Document Type: Review

References (43)

1. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr, J. L. et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 289, pp. 2560-2572.
2. World Health Report: Reducing risks, promoting health life (2002) World Health Organization, Geneva, Switzerland
3. Messerli, F. H., Williams, B. and Ritz, E. (2007) Essential hypertension. Lancet, 370, pp. 591-603.
4. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R. Germano, G. et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 25, pp. 1105-1187.
5. Bakris, G. L. (2008) Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich), 10:1, pp. 27-32.
6. Weber, M. A., Neutel, J. M. and Frishman, W. H. (2003) Combination drug therapy. Cardiovascular pharmacotherapeutics, pp. 355-368. McGraw-Hill, New York
7. Scholkens, B. A. and Landgraf, W. (2002) ACE inhibition and atherogenesis. Can J Physiol Pharmacol, 80, pp. 354-359.
8. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R. and Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342, pp. 145-153.
9. Schiffrin, E. L. and Deng, L. Y. (1996) Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens, 14, pp. 1247-1255.
10. Pitt, B., Byington, R. P., Furberg, C. D., Hunninghake, D. B., Mancini, G. B. Miller, M. E. et al. (2000) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation, 102, pp. 1503-1510.
11. Mason, R. P. (2001) Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am J Cardiol, 88, pp. 2M-6M.
12. Schiffrin, E. L., Deng, L. Y. and Larochelle, P. (1995) Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens, 8, pp. 229-236.
13. Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I. and Salvetti, A. (2000) Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep, 2, pp. 64-70.
14. Zhang, X., Xu, X., Nasjletti, A. and Hintze, T. H. (2000) Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol, 35, pp. 195-202.
15. Nissen, S. E., Tuzcu, E. M., Libby, P., Thompson, P. D., Ghali, M. Garza, D. et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA, 292, pp. 2217-2225.
16. Mason, R. P. (2003) Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: Evidence from clinical trials and basic scientific research. Cerebrovasc Dis, 16, pp. 11-17.
17. Jamerson, K. A., Bakris, G. L., Wun, C. C., Dahlof, B., Lefkowitz, M. Manfreda, S. et al. (2004) Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens, 17, pp. 793-801.
18. Weber, M. A., Bakris, G. L., Dahlof, B., Pitt, B., Velazquez, E. Gupte, J. et al. (2007) Baseline characteristics in the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Press, 16, pp. 13-19.
19. Kjeldsen, S. E., Jamerson, K. A., Bakris, G. L., Pitt, B., Dahlof, B. Velazquez, E. J. et al. (2008) Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. Blood Press, 17, pp. 7-17.
20. Jamerson, K., Weber, M. A., Bakris, G. L., Dahlof, B., Pitt, B. and Velazquez, E. (2008) Avoiding Cardiovascular events through COmbination therapy in Patients LIving with Systolic Hypertension: The ACCOMPLISH trial. 359, p. online November 28.
21. Jamerson, K., Bakris, G. L., Dahlof, B., Pitt, B., Velazquez, E. Gupte, J. et al. (2007) Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press, 16, pp. 80-86.
22. Kjeldsen, S., Oparil, S., Narkiewicz, K. and Hedner, T. (2008) A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH, and HYVET. Blood Press, 17, pp. 68-69.
23. Allemann, Y., Fraile, B., Lambert, M., Barbier, M., Ferber, P. and Izzo Jr, J. L. (2008) Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich), 10, pp. 185-194.
24. Quan, A., Chavanu, K. and Merkel, J. (2006) A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs, 6, pp. 103-113.
25. Kjeldsen, S. E., Aksnes, T. A., de la Sierra, A. and Ruilope, L. M. (2007) Amlodipine and valsartan: Calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy, 4, pp. 31-40.
26. Plosker, G. L. and Robinson, D. M. (2008) Amlodipine/valsartan: Fixed-dose combination in hypertension. Drugs, 68, pp. 373-381.
27. Chrysant, S. G., Melino, M., Karki, S., Lee, J. and Heyrman, R. (2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther, 30, pp. 587-604.
28. Poulter, N. R., Wedel, H., Dahlof, B., Sever, P. S., Beevers, D. G. Caulfield, M. et al. (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 366, pp. 907-913.
29. Dahlof, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G. Caulfield, M. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet, 366, pp. 895-906.
30. Neutel, J. M., Smith, D. H. G. and Weber, M. A. (2002) A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibility and left ventricular hypertrophy in patients with mild to moderate hypertension. Am J Hematol, 15:4, p. 166A.
31. Yusuf, S., Teo, K. K., Pogue, J., Dyal, L., Copland, I. Schumacher, H. et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 358, pp. 1547-1559.
32. Voors, A. A. and Van Veldhuisen, D. J. (2004) Role of angiotensin receptor blockers in patients with left ventricular dysfunction: Lessons from CHARM and VALIANT. Int J Cardiol, 97, pp. 345-348.
33. Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Kober, L. Maggioni, A. P. et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349, pp. 1893-1906.
34. Dickstein, K. and Kjekshus, J. (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 360, pp. 752-760.
35. Bhakta, S. and Dunlap, M. E. (2004) Angiotensin-receptor blockers in heart failure: Evidence from the CHARM trial. Cleve Clin J Med, 71, pp. 665-673.
36. Sica, D. A. (2004) ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) trials. Congest Heart Fail, 10, pp. 160-164.
37. Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L. Olofsson, B. et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet, 362, pp. 772-776.
38. Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J. Thomas, I. et al. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 349, pp. 747-752.
39. Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K. Camm, A. J. et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-The Losartan Heart Failure Survival Study ELITE II. Lancet, 355, pp. 1582-1587.
40. McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J. Probstfield, J. et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation, 100, pp. 1056-1064.
41. Dahlof, B. (2007) Prevention of stroke in patients with hypertension. Am J Cardiol, 100, pp. 17J-24J.
42. Matchar, D. B., McCrory, D. C., Orlando, L. A., Patel, M. R., Patel, U. D. Patwardhan, M. B. et al. (2008) Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med, 148, pp. 16-29.
43. Reboldi, G., Angeli, F., Cavallini, C., Gentile, G., Mancia, G. and Verdecchia, P. (2008) Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis. J Hypertens, 26, pp. 1282-1289.